Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.58 |
| ▸ | NPC1 | O15118 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.49 |
| ▸ | CTSK | P43235 | 1/20 | 0.43 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.42 |
| ▸ | CDK2 | P24941 | 2/20 | 0.42 |
| ▸ | GSK3B | P49841 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2736250 | 0.85 | TDP1 (0.57) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL10202835 | 0.85 | LMNA (0.58) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL2977720 | 0.85 | CYP3A4 (0.53) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| Hydrochloric Acid SCHEMBL271526 | 0.84 | CYP3A4 (0.52) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL2736245 | 0.83 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL4961426 | 0.83 | TDP1 (0.58) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL27817625 | 0.82 | TDP1 (0.59) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL11983270 | 0.82 | TDP1 (0.53) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL15046047 | 0.81 | RAB9A (0.63) | RAB9ANPC1SMN1; SMN2TDP1LMNA | |
| SCHEMBL893540 | 0.81 | NPC1 (0.51) | RAB9ANPC1SMN1; SMN2TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2018-08-09 | — | — | US | disclosed |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-06-08 | — | — | US | disclosed |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2017-05-25 | — | — | US | disclosed |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160067360-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160069915-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC, | 2016-03-10 | — | — | US | disclosed |
| US-9139541-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-20150225448-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2015-08-13 | — | — | US | disclosed |
| US-20150139948-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-20150011775-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140105859-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140017199-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. | 2014-01-16 | — | — | US | disclosed |
| US-8486942-B2 | Modulators of pharmacokinetic properties of therapeutics | Gilead Sciencs, Inc. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20130123311-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2013-05-16 | — | — | US | disclosed |
| US-8383655-B2 | Modulators of pharmacokinetic properties of therapeutics | GILEAD SCIENCES, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20120237478-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2012-09-20 | — | — | US | disclosed |
| US-20110212964-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | GILEAD SCIENCES, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140105859-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20130123311-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20140017199-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | RAB9A 1445/4885NPC1 46/4885SMN1; SMN2 581/4885 |
| US-20160303088-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20150139948-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | RAB9A 1445/4885NPC1 46/4885SMN1; SMN2 581/4885 |
| US-20120237478-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | RAB9A 1445/4885NPC1 46/4885SMN1; SMN2 581/4885 |
| US-20180221348-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20170158647-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, SLC26A4 | RAB9A 1445/4885NPC1 46/4885SMN1; SMN2 581/4885 |
| US-20150225448-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20170143680-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20160067360-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20150011775-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
| US-20110212964-A1 | MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS | SLC10A1, SLC10A2, ABCB11 | RAB9A 1234/4885NPC1 20/4885SMN1; SMN2 468/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.